Supply of Mylanta Original and Mylanta P Antacid (Johnson & Johnson)

Overview

The Therapeutic Goods Act 1989 is foundational legislation in Australia that governs the regulation of therapeutic goods, which include medicines, medical devices, blood, and tissues. Enacted by the Commonwealth Parliament, the Act was introduced to address the need for a comprehensive regulatory framework to ensure the safety, quality, and efficacy of therapeutic goods available to the public. The Act aims to protect public health by controlling the importation, supply, and advertising of therapeutic goods, among other objectives. One of the key mechanisms within the Act is the ability of the Delegate of the Secretary to the Department of Health to provide consent for certain goods to be supplied under specific conditions, as demonstrated by the notice issued for MYLANTA products by Johnson & Johnson Pacific Pty Ltd. This mechanism allows for flexibility in the regulatory approach while maintaining stringent controls to safeguard public health. The notice issued on 13 January 2014 by Mayada Kayali, as a Delegate, highlights the Act's practical application in addressing deviations from microbiological standards, ensuring that therapeutic goods meet the necessary safety requirements despite certain specified exceptions.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration, applies to a broad range of therapeutic goods including medicines, medical devices, blood and tissues within Australia. It sets out regulatory requirements for the supply, advertising, and import of these goods, ensuring they are safe, of acceptable quality, and their benefits outweigh any risks. The Act applies to entities and individuals involved in the manufacture, importation, supply, and advertising of therapeutic goods in Australia, covering all states and territories under the Commonwealth jurisdiction. Specific exclusions or exemptions may exist for certain classes of goods or activities, such as research activities or goods for personal use, as outlined in the various Therapeutic Goods Orders and Regulations. The Act's application can also be extended or restricted through subordinate instruments, which provide further detail on specific regulatory requirements and enforcement mechanisms. This consent notice under section 14A of the Act allows for specific exceptions to microbiological standards for certain products, subject to detailed conditions ensuring public safety and product quality.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) is a comprehensive piece of legislation that regulates the supply of therapeutic goods in Australia. Section 14 of the Act allows the Delegate of the Secretary to the Department of Health to give consent for the supply of therapeutic goods that do not fully comply with certain standards, while Section 14A provides for a notice to be issued in such cases. In this instance, the Delegate has granted consent for Johnson & Johnson Pacific Pty Ltd to supply MYLANTA ORIGINAL oral liquid bottle (AUST R 122007) and MYLANTA P ANTACID oral liquid bottle (AUST R 121994) (section 14(1)). However, this consent is subject to specific conditions, which include that the goods must comply with all other applicable requirements of Therapeutic Goods Order No. 77 - Microbiological Standards for Medicines (section 15(1)(a)) and that the consent is valid only for a period of three years from the date of the notice (section 15(1)(b)). The Act imposes several obligations on the parties it governs. Firstly, the Delegate of the Secretary is required to consider applications for consent and issue a notice when consent is granted (section 14A). Secondly, the supplier must ensure that the goods supplied comply with all conditions outlined in the notice (section 15(2)). Thirdly, the supplier must maintain records of the supply of the goods and make them available for inspection by the Therapeutic Goods Administration (section 15(3)). Lastly, the supplier must ensure that the goods are not supplied in a manner that would be misleading or deceptive (section 15(4)). Failure to comply with the conditions of the notice or any other requirements of the Act may result in civil or criminal consequences. For example, supplying goods that do not comply with the conditions of the notice may result in a civil penalty of up to $22,200 for an individual and $111,000 for a body corporate (section 37). In addition, supplying goods that are misleading or deceptive may result in a criminal offence and a fine of up to $1.1 million for an individual and $5.5 million for a body corporate (section 33). It is important for suppliers to ensure that they comply with all requirements of the Act to avoid any potential legal consequences.